Disclosed is a an anti-cancer agent for treating cancer in a subject comprising (i) in combination with (ii)； (i) one or more peptides inducing CTL selected from the group consisting of； (a) one or more peptides having the amino acid sequence selected from the group consisting of RFVPDGNRI (SEQ ID NO: 1), VYSSEEAEL (SEQ ID NO: 2), GYRIYDVVL (SEQ ID NO: 3), SYMISYAGM (SEQ ID NO: 4), KWEFPRDRL (SEQ ID NO: 5), and DFLTLEHLI (SEQ ID NO: 6), (b) the peptide of (a), in which 1, 2, or several amino acids are substituted, deleted, or added, and wherein said peptide has cytotoxic T cell inducibility； (c) the peptide of (b), wherein the second amino acid from the N-terminus is phenylalanine, tyrosine, methionine, or tryptophan； (d) the peptide of (b) or (c) , wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine； (e) one or more peptides having the amino acid sequence selected from the group consisting of AMFFWLLLV (SEQ ID NO: 7), VIAMFFWLL (SEQ ID NO: 8), AVIAMFFWL (SEQ ID NO: 9), KLIEIGVQT (SEQ ID NO: 10), YMISYAGMV (SEQ ID NO: 11), IQSDVWSFGV (SEQ ID NO: 12) and VLAMFFWLL (SEQ ID NO: 13)； (f) the peptide of (e), in which 1, 2, or several amino acids are substituted, deleted, or added, and wherein said peptide has cytotoxic T cell inducibility； (g) the peptide of (f), wherein the second amino acid from the N terminus is leucine or methionine； and (h) the peptide of (f) or (g), wherein the C-terminal amino acid is valine or leucine, (ii) one or more chemotherapeutic agents selected from the group consisting of gemcitabine, a pharmaceutically acceptable salt thereof, and a prodrug thereof.
